| News

BaseLaunch up to a solid Phase II start

30.01.2018

BaseLaunch has officially started Phase II of its accelerator program, and four startups are receiving grants ranging from 120,000 to 250,000 Swiss francs. This non-dilutive funding will help them to reach key value inflection milestones to advance their scientific hypothesis and further build their ventures, while learning and benefiting from the Basel life sciences ecosystem. Furthermore, two startups will gain access to the ready-to-use laboratory and office space, both free of charge, at the Switzerland Innovation Park Basel Area.

BaseLaunch Teams (img: Mathias Mangold)

BaseLaunch successfully ran its first acceleration phase from September to November 2017. During these three months, 11 healthcare ventures worked together with experienced advisors to further define and advance their projects. Activities included firming up their respective business opportunities, ensuring focus on the essential tasks to bring forward their ventures, but also identifying key risks and corresponding actions to address them. Furthermore, the projects benefited from accessing valuable industry knowledge and market know-how from seasoned professionals representing the BaseLaunch healthcare partners: Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences.

Trudi Haemmerli, who presides over the selection committee of BaseLaunch, explains which parameters were prioritized: “We focused on innovation, the quality of the people and the scientific evidence that was presented so far. Also we took in consideration if and how the project could benefit from the Basel life sciences cluster.” The selected projects are strongly committed to explore the Basel region and the talent the ecosystem has to offer, by having operations in the region.

BaseLaunch will support six projects in Phase II of the program: Anaveon, Tepthera, TheraNASH and T3 Pharmaceuticals will receive grants ranging from 120,000 to 250,000 Swiss francs. Furthermore, Polyneuron Pharmaceuticals and Versameb will gain access to the ready-to-use laboratory and office space, both free of charge, at the Switzerland Innovation Park Basel Area.

 

BaseLaunch started in 2017 to accelerate the development of promising and innovative healthcare startups benefiting from the dynamic life sciences cluster of the Basel region. During the first cycle, more than 100 projects from more than 30 countries applied, reaffirming the strong unmet need that BaseLaunch addresses. The healthcare partners played an active role by giving key strategic feedback to the projects. “We provided a highly customized program making the needs of the entrepreneurs and their ventures our key priorities,” says Alethia de León, Managing Director of BaseLaunch. “Now we are looking forward to helping the selected companies to move further in the venture creation process and to attract further investments.”

Applications for the BaseLaunch cycle of 2018 are now open. For more information on companies selected for Phase II and the application process, visit www.baselaunch.ch

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Basel Area Business & Innovation, Innovation

Polyneuron medication receives orphan drug status in the USA

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Read More
Basel Area Business & Innovation, Innovation

BaseLaunch Applications open

BaseLaunch helps build therapeutic ventures to the point where they can raise a Series-A financing round or similar.

Read More
Basel Area Business & Innovation, Innovation

i4Challenge Applications open

The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.

Read More
Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.